As shown in Figures 5A, B and Table 2, in general, there were no obvious distribution differences of TMB in most mutated genes between low and high SUMO score groups, but for some popular genes in bladder cancer studies such as TP53, RB1, and FGFR3, the mutation frequency difference between high and low SUMO score groups was more than 10%. This evidence concerns the gene TP53 and urinary bladder carcinoma.